Zabofloxacin

Summary

Zabofloxacin (CHEMBL2107811) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including chronic obstructive pulmonary disease and pneumonia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 401.4 Da · C19H20FN5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107811
Name	Zabofloxacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10388396
Molecular formula	C19H20FN5O4
Molecular weight	401.4
InChIKey	ZNPOCLHDJCAZAH-OEAKJJBVSA-N

SMILES: CO/N=C/1\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F

IUPAC name: 1-cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid

Also known as: Zabofloxacin, Zabofloxacine, Zabofloxacino, ZABOFLOXACIN

Patent coverage: 50 distinct patent families (145 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 136 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
pneumonia	2	MONDO:0005249	EFO:0003106

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01658020	PHASE3	COMPLETED	A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
NCT01081964	PHASE2	TERMINATED	Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
NCT02212795	PHASE1	COMPLETED	Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).